Re: Has a 3-Fold Decreased Dose of Bacillus Calmette-Guerin the Same Efficacy Against Recurrences and Progression of T1G3 and Tis Bladder Tumors Than the Standard Dose? Results of a Prospective Randomized Trial.

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1960-1961

  Inman, Brant A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; DISEASE PROGRESSION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS;

EID: 33646108599     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00970-5     Document Type: Letter

References (3)

1. Garrett A.D. Therapeutic equivalence. fallacies and falsification. Stat Med 22 (2003) 741
2. Altman D.G., Machin D., Bryant T.N., and Gardner M.J. Statistics With Confidence. 2nd ed. (2000), BMJ Books, Bristol, United Kingdom 240
3. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al., CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671